What is the appropriate evaluation for a patient with an elevated platelet count?

Evaluation of Elevated Platelet Count

For a patient with elevated platelets, immediately confirm the finding with a repeat CBC and peripheral blood smear to exclude pseudothrombocytopenia, then systematically distinguish between reactive (secondary) thrombocytosis—which accounts for approximately 80-88% of cases—and primary myeloproliferative neoplasms through targeted molecular testing and bone marrow evaluation when indicated 1, 2, 3.

Initial Confirmation and Assessment

Start by repeating the platelet count to confirm true thrombocytosis (platelet count ≥450 × 10³/μL) 4. Collect blood in heparin or sodium citrate tubes to exclude pseudothrombocytopenia from platelet clumping. Order a peripheral blood smear examination immediately to assess platelet morphology and evaluate other cell lines 1.

Key Clinical Features to Identify

Look specifically for:

• Microvascular symptoms: headaches, paresthesias, erythromelalgia (burning pain in extremities)
• Splenomegaly on physical examination
• History of thrombosis or unexplained bleeding
• Underlying conditions: recent surgery, tissue damage, active infection, malignancy, chronic inflammatory disease, iron deficiency 1, 2

Diagnostic Algorithm

Step 1: Rule Out Secondary Causes

The vast majority (82-88%) of thrombocytosis cases are reactive 2, 3. Order:

• C-reactive protein and inflammatory markers
• Iron studies with ferritin (iron deficiency is a common cause)
• Comprehensive metabolic panel with LDH and liver function tests
• Review for: tissue damage (42% of secondary cases), infection (24%), malignancy (13%), chronic inflammation (10%) 2

Critical distinction: Secondary thrombocytosis rarely causes thrombotic complications unless other risk factors are present, and venous events predominate when they occur 2. Primary thrombocytosis carries significantly higher risk for both arterial and venous thrombosis (56% vs 4% symptomatic rate) 3.

Step 2: If No Secondary Cause Identified—Test for Myeloproliferative Neoplasms

When persistent thrombocytosis remains unexplained after excluding reactive causes, proceed with molecular testing 1, 4:

1. JAK2 V617F mutation testing (first-line)
2. If JAK2 negative: Test for CALR and MPL mutations
3. BCR-ABL1 testing (FISH or RT-PCR) to exclude chronic myeloid leukemia 1

Step 3: Bone Marrow Evaluation

Perform bone marrow aspirate and biopsy with reticulin and trichrome staining when 1:

• Molecular testing suggests myeloproliferative neoplasm
• Clinical suspicion remains high despite negative molecular tests
• Need to distinguish essential thrombocythemia from early myelofibrosis

Bone marrow findings help differentiate entities:

• Essential thrombocythemia: Giant megakaryocytes with deeply lobulated (staghorn-like) nuclei, minimal reticulin fibrosis 5
• Polycythemia vera: Pleomorphic megakaryocytes, panmyelosis, absent iron stores 5
• Early myelofibrosis: Atypical megakaryocytes, variable reticulin fibrosis 5

Step 4: Additional Testing for Specific Scenarios

For patients with elevated platelets AND 1:

• Undergoing high-risk surgery: Coagulation tests for acquired von Willebrand disease (VWF antigen, Factor VIII activity, VWF multimers)
• Unexplained bleeding: Same coagulation panel
• Splenomegaly: Same coagulation panel

Extreme Thrombocytosis (≥1,000 × 10³/μL)

When platelet counts exceed 1,000 × 10³/μL, the distribution shifts but secondary causes still predominate (66-82%) 6, 3. However, bleeding and vaso-occlusive complications occur in 56% of myeloproliferative disorder cases versus only 4-7.9% of reactive cases 6, 3. This warrants more aggressive evaluation for primary causes even when secondary triggers are present.

Common Pitfalls to Avoid

• Don't assume extreme thrombocytosis equals malignancy: Most cases >1,000 × 10³/μL are still reactive 3
• Don't skip iron studies: Iron deficiency commonly causes reactive thrombocytosis and is easily missed
• Don't delay molecular testing when no secondary cause is apparent—early diagnosis of essential thrombocythemia impacts thrombosis risk stratification 4
• Don't forget BCR-ABL1 testing: Chronic myeloid leukemia can present with thrombocytosis and requires different management 1

Risk Stratification After Diagnosis

If essential thrombocythemia is confirmed, calculate the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia to guide decisions about aspirin therapy and cytoreductive treatment 4. Refer all confirmed myeloproliferative neoplasm patients to specialized centers 1.